BRM:FRA
Bristol-Myers Squibb Co
€51.01
arrow_upward
+1.07%(+0.54) 1D
Oct 14, 10:57:11 AM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BRM...
Open
€50.51
High
€51.01
Low
€50.51
Mkt. cap
115.76B
Avg. vol.
224.00
Volume
40.00
52-wk high
€60.64
52-wk low
€36.65
No. of employees
32K
Open
€50.51
High
€51.01
Low
€50.51
Mkt. cap
115.76B
Avg. vol.
224.00
Volume
40.00
52-wk high
€60.64
52-wk low
€36.65
No. of employees
32K
News stories
From web sources and news partners
BioSpace
·
1 hour ago
J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback
ad-hoc-news.de
·
5 hours ago
Bristol Myers Squibb reports two Phase 3 updates: stock pre-market at EUR 50.67
The Motley Fool
·
13 hours ago
Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?
Trefis
·
15 hours ago
What Does Bristol-Myers Squibb Offer That Pfizer Does Not?
Profile
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States.
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
About Bristol-Myers Squibb Co
CEOChris Boerner
Employees32.5K
Founded1887
HeadquartersNew York, New York, United States
SectorPharmaceutical industry
Websitebms.com